IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Endologix, Inc. (“Endologix” or the “Company”) (Nasdaq: ELGX) concerning possible violations of federal securities laws.
If you purchased shares of Endologix and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
Nellix is Endologix’s endovascular aneurysm sealing system used against infrarenal abdominal aortic aneurysms. Endologix allowed the Nellix system to be applied in the Nellix investigational device exemption (IDE) clinical trial, the EVAS FORWARD-IDE Study. However, Endologix revealed that the FDA asked for a follow-up on patients in the EVAS-FORWARD-IDE study to measure Nellix. On December 27, 2016 Endologix revealed that it was barring AFX Endovascular AAA System shipments indefinitely because of a manufacturing investigation. When this news was shared with the investing public, Endologix stock fell, causing shareholders severe harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.